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(2DE), and biplanemethod of discs frommultiplane images and the frustumof 3DE,
aswell as direct volumemeasurementwith 3DE. Agreement betweenmethodswas
analyzed using amodified Bland-Altman plot. RESULTS:When comparingwith the
direct 3DE measurement of volume, calculated volumes were slightly underesti-
mated with 3DE, and increasingly underestimated with 2DE. However, the devia-
tions were predictable for the respective dog sizes. Results from M-Mode unpre-
dictably overestimated volume of the left ventricle. CONCLUSIONS: When
considering the direct measurement of volume as being the most reliable method,
other measurements performed with 3DE resulted in highest consistency. Results
obtained with 2DE revealed higher but still predictable deviations, whereas results
from M-Mode were highly and unpredictably deviating. Accordingly, 3DE has the
potential to becomeanewstandard in dogs inwhichMRI is not indicated. However,
further clinical and economic evaluations are needed in veterinary cardiology.
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OBJECTIVES: Despite limited evidence, US and European guidelines recommend
the use of IV vasodilators in addition to diuretics for the treatment of acute heart
failure (AHF) patients who are not hypotensive. We investigated whether patients
hospitalized for AHF and treated with IV loop diuretics in combination with IV
nitrates (NT) or IV nesiritide (NES) achieve better outcomes compared to those
receiving diuretics alone.METHODS:UShospital records (2007-2009) from theMar-
ketscan Hospital Drug Database were analyzed to identify patients first observed
hospitalization with a primary diagnosis of AHF. Patients 18 years old, with hy-
potension, cardiogenic shock, myocardial infarction, and acute coronary syn-
dromes were excluded. Patients receiving diuretics were matched pair-wise with
patients receiving diureticsNT or diureticsNES using the propensity score ap-
proach. Outcomes included in-hospital mortality, hospital length of stay (LoS), and
costs during the first AHF hospitalization. RESULTS:DiureticsNT (N4,401; mean
age 70.1 years, 49.2% male) and diureticsNES (N2,254; mean age 70.4 years,
59.4% male) patients had longer LoS (7.3 and 7.9 days, respectively) vs. diuretic
patients (5.7 and 5.8 days for corresponding pairs; p0.01). LoS in ICUwas about 0.7
days longer (p0.01) in both vasodilator cohorts vs. diuretics alone. Mortality was
similar to diuretics patients among diureticsNT patients (1.9% vs. 2.0%; p0.88)
but higher among diureticsNES patients (2.2% vs. 3.1%; p0.05). Hospitalization
costs were significantly greater in both vasodilator cohorts (diuretics: $8,949 vs.
diureticsNT: $14,016, p0.01; diuretics: $9,057 vs. diureticsNES: $14,210,
p0.01). CONCLUSIONS: This real-world study of patients hospitalized for AHF
indicates that neither NT nor NES in addition to diuretics improve survival com-
pared to diuretics alone, and are associated with both longer LoS (1.5 days) and
higher (57%) hospitalization total costs. These data raise the question as towhether
currently utilized IV vasodilators are of value in the treatment of patient hospital-
ized for AHF.
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OBJECTIVES: Cardiovascular health disparities continue to pose a major public
health problem. We hypothesize that the use of existing social networks in hyper-
tension management can help hypertension control rates. Through the Maryland
Cardiovascular Promotion Program (MVP), we evaluated the effect of education
administered within social clusters on the improvement of blood pressure in Afri-
can Americans in the Baltimoremetropolitan area.METHODS:MVP patients, com-
pared to historical controls, were enrolled in the intervention group and asked to
recruit peers to the program and form small groups to attend monthly hyperten-
sion education sessions. Hypertensionwas identifiedwhen systolic blood pressure
(SBP) 140mmHg or/and diastolic blood pressure (DBP) 90mmHg; and SBP 130
mmHg or/and DBP80 mmHg in those with diabetes. We built binary logit regres-
sion models at follow-up of 6, 12, and 18 months, to assess the likelihood of reach-
ing goal (130/80 mmHg for diabetics and 140/90 mmHg for others), controlling for
group assignment, diabetes, smoking, baseline hypertension, and demographics.
We also built regression models for absolute reduction in BP. RESULTS: Out of 530
patients, most were African American. In the adjusted models, the MVP group had
a larger drop in mean absolute SBP than the control, with the gap growing larger
over time. The MVP group was more likely to ever reach treatment goal at 18
months (OR1.72, P0.06), and more likely to reach goal more than once at 12
months (OR2.61, P0.03) and 18 months (OR19.1, P0.001) of follow-up.
CONCLUSIONS: The clustering of patients in social networks around hypertension
education has a positive impact on the management of hypertension. Such ap-
proaches based on existing social networks in minority populations may help im-
prove cardiovascular outcomes and address health disparities.
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OBJECTIVES: Few studies have estimated the dynamic changes and lifetime scores
of quality of life (QOL) among different types of ischemic stroke. The aim of this
study was to quantify these to assist clinical decision. METHODS: The hospital-
based cohort, which consisted of 10,102 patients with first-ever ischemic stroke
during 1995-2007, was classified into 5 types: large artery atherosclerosis (LAA),
lacune, cardioembolism, other determined, and undetermined etiologies. After
linking with the National Mortality Registry 1995-2008, survival function were de-
termined and extrapolated over a 600-month period based on the survival ratio
between the patient’s and age- and sex- matched reference group’s survival as
estimated by a semi-parametric method and hazard functions taken from the vital
statistics of Taiwan. WHOQOL-BREF questionnaire were administered on a cross-
sectional sample of 748 patients to estimate the dynamic changes along different
duration-to-dates. The survival functionswere thenmultipliedwith different facet
scores of QOL to obtain the lifetime scores for patients with different types of
ischemic stroke. Multiple regression analyses were conducted to explore the ef-
fects of different risk factors for QOL after adjustments for age, sex, and education.
RESULTS: Patients with LAA seemed to be affected the most in both survival and
many facets of QOL, as demonstrated by lifetime scores of 35.6 (2.8), 31.7 (3.2), 32.7
(2.5) and 33.2 (3.2) score-months in mobility, positive feelings, sexual activity and
participation in and opportunities for recreation or leisure, respectively. Compared
with other types, cardio-embolism appeared to be affected the most over mobility,
activities of daily living, work ability, thinking and learning. CONCLUSIONS:
Among different types of ischemic stroke, LAA seemed the worst in both QOL and
survival; cardio-embolism showed the longest survival but poor QOL, indicating a
possible greater demand for long term care.
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OBJECTIVES: To examine the relationship between adherence to colesevelam and
risk of major cardiovascular events among hyperlipidemia and/or type 2 diabetes
mellitus (T2DM) patients newly treated with colesevelam. METHODS: The study
sample consisted of hyperlipidemia and/or T2DM patients inMarketScan database
who newly initiated colesevelam with at least 6 and 12 months continuous enroll-
ment prior- and post- drug initiation date in 2007-2010, respectively. Adherence to
colesevelam was measured as Medication Possession Ratio (MPR), calculated as
total days of supply during a one-year period after drug initiation date (adherence
cohort assignment period [ACAP]) divided by 365. Patients were assigned to one of
three adherence cohorts (High: MPR0.8, medium: 0.5MPR0.8, low:
MPR0.5.). The outcome was the time to the first hospitalization with a primary
diagnosis for AMI or stroke during the follow up period from the end of ACAP to the
end of enrollment period in the database. Association of colesevelam adherence
with the outcome was examined by multivariate Cox regression, adjusting for
patient demographic and clinical characteristics. RESULTS: A total of 31,017 pa-
tients were included in the analysis, of which 5,696 (18.4%), 4,643 (15.0%), 20,678
(66.7%) were high, medium and low adherence, respectively. Compared to patients
with low adherence, high adherence patients were 41% less likely to experience
AMI or stroke hospitalization during the follow up period (Hazard Ratio: 0.59; 95%
CI, 0.41 – 0.84, P0.004). Other factors associatedwith significantly lower risk of AMI
or stroke hospitalization included female gender, younger age, absence of baseline
transient ischemic attack or coronary heart disease, absence of concomitant use of
aliskiren, insulin or metformin, and absence of AMI or stroke during ACAP.
CONCLUSIONS: High adherence to colesevelam was associated with significantly
lower risk of major cardiovascular events (AMI and stroke). This finding suggests
that adhering to colesevelam therapy may provide long-term cardiovascular
benefits.
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OBJECTIVES: To evaluate the response to 600 mg Clopidogrel loading dose versus
300 mg loading dose in patients undergo PCI. METHODS: A total of 51 patients
categorized to two groups: Group I consisted of 11 males (64.7%) and 6 females
(35.3%) received 300 mg loading does, while Group II consisted of 28 males (82.4%)
and 6 females (17.6%) received 600mg Clopidogrel loading does. Detection of Clopi-
dogrel response was assessed bymeasuring of the platelet aggregation percentage
and CYP2C19 *2 assay in both groups. Clopidogrel resistance was defined by an
arbitrary cut off value of 10% with respect definition as compared to control value.
RESULTS: The percentage of Clopidogrel response among the studied patients
was 29.2% for 300mg Clopidogrel and 70.8% for 6oomg Clopidogrel loading dose.
In non or poor response to Clopidogrel group 10 patients (37%), were resistance
to 300mg dose and 17 patients (63%) were resistance to 600mg Clopidogrel dose.
Clopidogrel resistance groups were more likely have CYP2C19 genotype
(CYP2C19*1.CYP2C19*2) (GA). There were highly significant association between
good response group, non and poor response groups as regarding to genotype
CYP2C19*1,CYP2C19*1 (GG) carriers and CYP2C19*1,CYP2C19*2 (GA) carriers. Plate-
let aggregation after 600mg Clopidogrel in both CYP2C19*1, CYP2C19*1 (GG) carriers
and CYP2C19*1, CYP2C19*2(GA) carriers is statistically non significant with basal
aggregation, before PCI and after PCI, while significantwith day after PCI andhighly
significant with inhibition percentage before PCI. Platelet aggregation after 300mg
Clopidogrel in both CYP2C19*1, CYP2C19*1 (GG) carriers and CYP2C19*1,
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CYP2C19*2(GA) carries is a statistically non significant with basal aggregation, be-
fore PCI, day after PCI, and after PCI, while significant with inhibition percentage
before PCI.CONCLUSIONS: Therewas a variable individual response to Clopidogrel
between patients carries CYP2C19*1.CYP2C19*2 (GA) genotype and carries
CYP2C19*1.CYP2C19*1 (GG) genotype.
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OBJECTIVES: This study examined VTE prophylaxis and VTE risk reduction and
readmission in a cohort of hospitalized medically ill patients in the real-world
clinical setting during hospitalization and post discharge. METHODS: This 5-year
retrospective study used linked outpatient files from MarketScan® Commercial
and Medicare Supplemental databases, thereby providing continuity of therapy
through hospitalization and post-discharge. Patients were categorized into pro-
phylaxis and non-prophylaxis groups based on use of any guideline-recommended
anticoagulants from the index date to 180 days after index hospital discharge, and
before the date of the first VTE event. Outcome variables were VTE events and
re-hospitalization. Risk adjustment was conducted within the prophylaxis group,
and between the prophylaxis and non-prophylaxis groups using propensity score
matching. RESULTS: Among 3916 patients identified, 29.37% (n1295) were admit-
ted with cancer, 18.25% (n805) with pneumonia, 14.24% (n628) with heart fail-
ure, 11.25% (n496) with sepsis, 8.19% (n361) with infectious diseases, 5.67%
(n250) with severe respiratory disorders, and 1.84% (n81) with inflammatory
bowel disease (IBD). Among these patients, only 1819 (51.81%) received anticoagu-
lant therapy and 242 (6.18%) received non-pharmacological prophylaxis only dur-
ing their hospitalization and until 180 days after discharge. The anticoagulant
therapy rates ranged from 88.64% in obesity to 32.39% in IBD patients. Among
patients who received anticoagulant therapy, 740 (40.68%) received low molecular
weight heparin only and 806 (44.31%) received unfractionated heparin. After risk
adjustment, compared to patients without VTE prophylaxis, those patients who
received anticoagulant prophylaxis had lower VTE rates (3.62% vs. 4.27%., p0.04)
and lower readmission rates (24.22% vs 27.95%, p0.02) during the 6-month period
from the index hospital admission. CONCLUSIONS: Despite existing guidelines,
anticoagulant prophylaxis is underutilized inmedically ill patients in clinical prac-
tice. Anticoagulant prophylaxis is associated with reduced risk of VTE and rehos-
pitalization in medically ill patients.
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OBJECTIVES: The association of antihypertensive medication adherence with oc-
currence of complications and all-cause medical costs was examined using data
from the Health Insurance Review and Assessment Service(HIRA).METHODS: This
studywas a retrospective analysis of HIRA administrative claims data from January
2005 to December 2009. All subjects initiating therapy with oral antihypertensive
drugs were identified in January through December 2006. The index date was the
date of the first hypertension-related prescription. Patients were observed for 1
year before and 3 years after therapy initiation. Outcomes included occurrence of
complications and all-cause medical costs; occurrence of complications was mea-
sured starting 2 years after therapy initiation through follow-up and all-causemed-
ical costsweremeasured all durations of follow-up. Adherencewasmeasuredwith
a medication possession ratio (MPR) and categorized 19%, 20-39%, 40-59%, 60-
79%, and 80%. Using Cox survival regression, Occurrence of complications was
modeled at levels of MPR. All-cause medical costs were modeled with generalized
linear model regression. RESULTS: Average MPR in the total of 290,602 hyperten-
sion patients was 82.8%(21.2). In Cox survival analysis, risk of complications in-
creased as levels of MPR decreased. Patients with the lowest MPR level versus
optimal adherence had 3 times higher risk of complications (hazard ratio3.00,
95%CI2.69-3.35). Under the adjustmentwith covariates, annual all-causemedical
costs per patient were 23% higher for patients with the lowest MPR level versus
optimal level (exponential coefficient1.23, 95% CI1.20-1.25). The costs, however,
were 2-7% lower for groups with MPR 20-39%, 40-59% and 60-79%, because phar-
macy costs offset in/out-patient care cost saving. CONCLUSIONS: This study
showed strong associations between decreased antihypertensive medication ad-
herence and increased risk of complication occurrence. And the lowest adherence
was associated with higher all-cause medical costs. Further research is needed in
longer than 3 year follow-ups to assess the economic impact of adherence.
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OBJECTIVES: To compare baseline characteristics and dosage patterns among Jap-
anese patients newly started on statin. METHODS: Patients 18 years were iden-
tified between June 2006 to August 2010, with a minimum 6-month pre- and 12-
month post-index health plan eligibility from the Japan Medical Data Center
Database. A 90-day statin-free washout period was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription. Five cohorts were created based on index statins
[atorvastatin (ATS), simvastatin (SIS), rosuvastatin (ROS), pitavastatin (PTA), and
pravastatin (PRS)] comparing demographics, comorbidities, statin dosage patterns,
prior medication, health care costs and resource utilization. RESULTS: There were
14,675 patients identified across 5 cohorts: 27.7% ATS, 6.4% SIS, 26.9% ROS, 12.9%
PTA and 26.0% PRS. PTA cohort had more diabetes (PTA 14.0% vs. ATS 10.2%, SIS
6.5%, ROS 12.8%, PRS 9.6%) and coronary artery diseases (PTA 8.6% vs. ATS 7.7%, SIS
4.1%, ROS 7.4%, PRS 7.3%). ROS cohort had more prior peripheral vascular disease
(ROS 6.6% vs. ATS 5.6%, SIS 3.6%, PTA 5.6%, PRS 5.5%), cerebrovascular disease (ROS
7.0% vs. ATS 6.6%, SIS 2.9%, PTA 5.7%, PRS 6.3%), and hypertension (ROS 33.2% vs.
ATS 30.2%, SIS 27.4%, PTA 30.9%, PRS 30.2%). SIS cohort hadmore prior outpatients
visits (SIS 9.6 vs. ATS 8.2, ROS 8.7, PTA 8.2, PRS 9.3). Prior healthcare costs were
similar across 5 cohorts. Majority of patients were prescribed lower statin doses:
ATS, 10mg (60%); SIS, 5mg (86%); ROS, 2.5mg (89%); PTA, 1mg (49%); PRS, 10mg
(62%).CONCLUSIONS: Japanese patients newly started on a statin had similar prior
health care costs, andwere prescribed lower doses compared toWestern countries.
Patients with diabetes and coronary artery diseases were more likely to be pre-
scribed PTA.
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TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH PULMONARY
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HYPERTENSION: RESULTS OF A RETROSPECTIVE CHART REVIEW IN SIX
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OBJECTIVES: To describe demographics, treatment patterns and outcomes of pa-
tients with pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) treated under everyday practice.METHODS: Ret-
rospective chart review of PAH (N285) and CTEPH (N120) patients treated with
endothelin receptor antagonists, prostacyclin analogues or PDE-5 inhibitors be-
tween July 2003 and June 2009 in specialized centers in 6 countries (France, Ger-
many, Italy, Spain, Sweden, and United Kingdom). Data were extracted from pa-
tient files and analyzed descriptively. For survival analysis, Kaplan-Meier
estimates were used. RESULTS: PAH patients (idiopathic 49.8%, mean age
55.315.6 years, 74.4% females, 6-min-walk-distance [6-MWD] 328121 meters,
NYHA class II/III/IV in 20/66/14%) and CTEPH patients (83.7% inoperable and 15.8%
persistent after surgery, 67.512.1 years, 60.0% females, 6-MWD 298120 meters,
NYHA II/III/IV in 27/58/15%). Mean pulmonary arterial pressure was 5016 mmHg
in PAH and 4511 mmHg in CTEPH. Mean pulmonary vascular resistance was
939760 dyn*s*cm-5 in PAH and 797726dyn*s*cm-5 in CTEPH. At baseline, 93.7%
PAH patients received monotherapy (bosentan 47.0%, sildenafil 35.8%), with con-
comitant diuretics (40.0%) and anticoagulants (30.2%). CTEPH patients received
monotherapy in 99.2% (bosentan 56.7%, sildenafil 34.8%), with concomitant diuret-
ics (59.2%) and anticoagulants (62.5%). Mean observation time was 2.2 years (PAH)
and 2.1 years (CTEPH). At end of observation, in the PAH group mean 6-MWD
increased by 3291 meters and by 3090 in the CTEPH group. In the PAH group,
29.1% of patients improved, 63.8%were unchanged, 7.1% deteriorated in the NYHA
class, and 20.4% died (annualized death rate 10.3%); in the CTEPH group 32.2%
improved, 59.3% were unchanged, 8.5% deteriorated, and 13.3% died (annualized
death rate 6.4%). CONCLUSIONS: These data reflect real-life treatment patterns in
PAH and CTEPH patients in a period when several new PAH-specific treatments
were introduced. Overall, drug utilization was similar in PAH and CTEPH patients
(although off-label in the latter group). In viewof outcomes there still a great unmet
need, especially for patients with CTEPH.
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OBJECTIVES: The aims of this contribution are to update andmore precisely quan-
tify the age and gender-specific prevalence and incidence of atrial fibrillation (AF)
in an European setting (Germany).METHODS:To fulfill the aims of the study, it was
decided to make a population-based analysis of the claims data collected by a
statutory health insurance fund, and concerning its 8.298 million members. A pa-
tient was classified as AF prevalent if he/she had received at least two outpatient
diagnoses of AF (ICD10-Code I48.1) in two different quarters of the year and/or had
received at least one main AF diagnosis during inpatient treatment between Janu-
ary 1, 2007 andDecember 31, 2008. A patientwas considered to have had new onset
AF in 2008 under one of three conditions; firstly, he/she had not received a diagno-
sis of AF in 2007; secondly, had not received oral anticoagulant medication in 2007;
and thirdly, had received either one inpatient AF diagnosis in 2008, or two such
outpatient diagnosis made in different quarters of that year. AF prevalence is re-
ported in %, AF incidence is reported as cases per 1000 person-years. RESULTS: In
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